<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349632</url>
  </required_header>
  <id_info>
    <org_study_id>CLE383-C004</org_study_id>
    <nct_id>NCT03349632</nct_id>
  </id_info>
  <brief_title>Clinical Comparison of 4 Daily Disposable Soft Contact Lenses</brief_title>
  <official_title>Clinical Comparison of 4 Daily Disposable Soft Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain on-eye performance data to inform contact lens product
      development and to further evaluate product performance in the intended population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The expected duration of subject participation in the study is approximately 20 days with 3
      scheduled visits. Each subject will evaluate the test contact lenses compared to 1 of 3
      commercially available contact lenses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Actual">February 16, 2018</completion_date>
  <primary_completion_date type="Actual">February 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Quality of Vision</measure>
    <time_frame>Day 8, each product</time_frame>
    <description>Overall quality of vision was collected binocularly and rated on a 10-point scale with 1 = poor to 10 = excellent. Subjects were asked &quot;Thinking back over the last week, please rate our study lenses. Rate eyes together.&quot; No formal hypotheses was conducted; hence no inferential testing was performed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>DD T2/Oasys 1-Day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DD T2/MyDay</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DD T2/Moist</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>verofilcon A contact lenses</intervention_name>
    <description>Investigational spherical silicone hydrogel contact lenses for daily disposable wear</description>
    <arm_group_label>DD T2/Moist</arm_group_label>
    <arm_group_label>DD T2/MyDay</arm_group_label>
    <arm_group_label>DD T2/Oasys 1-Day</arm_group_label>
    <other_name>DDT2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A contact lenses</intervention_name>
    <description>Commercially available spherical silicone hydrogel contact lenses for daily disposable wear</description>
    <arm_group_label>DD T2/Oasys 1-Day</arm_group_label>
    <other_name>ACUVUE OASYS® 1-Day with HydraLuxe™ Technology</other_name>
    <other_name>Oasys 1-Day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stenfilcon A contact lenses</intervention_name>
    <description>Commercially available spherical silicone hydrogel contact lenses for daily disposable wear</description>
    <arm_group_label>DD T2/MyDay</arm_group_label>
    <other_name>MyDay®</other_name>
    <other_name>MyDay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A contact lenses</intervention_name>
    <description>Commercially available spherical silicone hydrogel contact lenses for daily disposable wear</description>
    <arm_group_label>DD T2/Moist</arm_group_label>
    <other_name>1-Day ACUVUE® MOIST</other_name>
    <other_name>Moist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and must sign an approved Informed Consent Form

          -  Successfully wears daily disposable spherical soft contact lenses in both eyes for a
             minimum of 5 days per week and 8 hours per day during the past 3 months

          -  Best Corrected Visual Acuity of 20/25 Snellen or better in each eye

          -  Willing to stop wearing habitual contact lenses for the duration of study
             participation

          -  Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Any eye condition, surgery, disease, or use of medication that contraindicates contact
             lens wear, as determined by the Investigator.

          -  Routinely sleeps in habitual contact lenses

          -  Currently wears Oasys 1-Day, MyDay, or Moist contact lenses

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Johns Creek</city>
        <state>Georgia</state>
        <zip>30097</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=17325</url>
    <description>Results from the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>January 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact lenses</keyword>
  <keyword>Myopia</keyword>
  <keyword>Near-sighted</keyword>
  <keyword>Daily disposable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03349632/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03349632/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 3 investigational sites located in the United States.</recruitment_details>
      <pre_assignment_details>Of the 68 enrolled, 2 subjects exited as screen failures prior to randomization. This reporting group includes all randomized subjects (66).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DD T2/Oasys 1-Day (Sequence 1)</title>
          <description>Verofilcon A contact lenses worn in Period 1, followed by senofilcon A contact lenses worn in Period 2. Each product worn bilaterally (in both eyes) for 1 week on a daily wear basis, as randomized</description>
        </group>
        <group group_id="P2">
          <title>Oasys 1-Day/DD T2 (Sequence 2)</title>
          <description>Senofilcon A contact lenses worn in Period 1, followed by verofilcon A contact lenses worn in Period 2. Each product worn bilaterally for 1 week on a daily wear basis, as randomized</description>
        </group>
        <group group_id="P3">
          <title>DD T2/MyDay (Sequence 3)</title>
          <description>Verofilcon A contact lenses worn in Period 1, followed by stenfilcon A contact lenses worn in Period 2. Each product worn bilaterally for 1 week on a daily wear basis, as randomized</description>
        </group>
        <group group_id="P4">
          <title>MyDay/DD T2 (Sequence 4)</title>
          <description>Stenfilcon A contact lenses worn in Period 1, followed by verofilcon A contact lenses worn in Period 2. Each product worn bilaterally for 1 week on a daily wear basis, as randomized</description>
        </group>
        <group group_id="P5">
          <title>DD T2/Moist (Sequence 5)</title>
          <description>Verofilcon A contact lenses worn in Period 1, followed by etafilcon A contact lenses worn in Period 2. Each product worn bilaterally for 1 week on a daily wear basis, as randomized</description>
        </group>
        <group group_id="P6">
          <title>Moist/DD T2 (Sequence 6)</title>
          <description>Etafilcon A contact lenses worn in Period 1, followed by verofilcon A contact lenses worn in Period 2. Each product worn bilaterally for 1 week on a daily wear basis, as randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, First Week of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, Second Week of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all subjects/eyes exposed to any study lenses evaluated in this study (Safety Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Verofilcon A contact lenses with corresponding control product (senofilcon A, stenfilcon A, or etafilcon) worn during Period 1 and Period 2 in a crossover assignment, as randomized.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Quality of Vision</title>
        <description>Overall quality of vision was collected binocularly and rated on a 10-point scale with 1 = poor to 10 = excellent. Subjects were asked &quot;Thinking back over the last week, please rate our study lenses. Rate eyes together.&quot; No formal hypotheses was conducted; hence no inferential testing was performed.</description>
        <time_frame>Day 8, each product</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>DD T2 (Sequence 1 and 2)</title>
            <description>Verofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
          </group>
          <group group_id="O2">
            <title>Oasys 1-Day (Sequence 1 and 2)</title>
            <description>Senofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
          </group>
          <group group_id="O3">
            <title>DD T2 (Sequence 3 and 4)</title>
            <description>Verofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
          </group>
          <group group_id="O4">
            <title>MyDay (Sequence 3 and 4)</title>
            <description>Stenfilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
          </group>
          <group group_id="O5">
            <title>DD T2 (Sequence 5 and 6)</title>
            <description>Verofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
          </group>
          <group group_id="O6">
            <title>Moist (Sequence 5 and 6)</title>
            <description>Etafilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Quality of Vision</title>
          <description>Overall quality of vision was collected binocularly and rated on a 10-point scale with 1 = poor to 10 = excellent. Subjects were asked &quot;Thinking back over the last week, please rate our study lenses. Rate eyes together.&quot; No formal hypotheses was conducted; hence no inferential testing was performed.</description>
          <population>Safety Analysis Set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="1.4"/>
                    <measurement group_id="O2" value="9.2" spread="1.3"/>
                    <measurement group_id="O3" value="8.8" spread="1.8"/>
                    <measurement group_id="O4" value="9.4" spread="0.8"/>
                    <measurement group_id="O5" value="9.2" spread="1.1"/>
                    <measurement group_id="O6" value="8.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Dispense through study completion, an average of 2 weeks</time_frame>
      <desc>An adverse event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users, or other persons, whether or not related to the investigational medical device. AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. Safety Analysis Set, based on treatment-specific exposure.</desc>
      <group_list>
        <group group_id="E1">
          <title>DD T2 (Sequence 1 and 2)</title>
          <description>Verofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
        </group>
        <group group_id="E2">
          <title>Oasys 1- Day (Sequence 1 and 2)</title>
          <description>Senofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
        </group>
        <group group_id="E3">
          <title>DD T2 (Sequence 3 and 4)</title>
          <description>Verofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
        </group>
        <group group_id="E4">
          <title>MyDay (Sequence 3 and 4)</title>
          <description>Stenfilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
        </group>
        <group group_id="E5">
          <title>DD T2 (Sequence 5 and 6)</title>
          <description>Verofilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
        </group>
        <group group_id="E6">
          <title>Moist (Sequence 5 and 6)</title>
          <description>Etafilcon A contact lenses worn in Period 1 or Period 2 for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Clinical Project Lead, GCRA - Vision Care</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

